Cellectis S.A. (0WA2.IL)
- Previous Close
1.4050 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 2.9100 - Volume
0 - Avg. Volume
2,408 - Market Cap (intraday)
99.354M - Beta (5Y Monthly) 2.09
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4200 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
www.cellectis.comRecent News: 0WA2.IL
View MorePerformance Overview: 0WA2.IL
Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0WA2.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0WA2.IL
View MoreValuation Measures
Market Cap
186.28M
Enterprise Value
36.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.45
Price/Book (mrq)
1.21
Enterprise Value/Revenue
1.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.04%
Return on Equity (ttm)
-62.86%
Revenue (ttm)
24.76M
Net Income Avi to Common (ttm)
-77.16M
Diluted EPS (ttm)
-1.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
84.39M
Total Debt/Equity (mrq)
90.58%
Levered Free Cash Flow (ttm)
-50.66M